Barrick Mining Corporation Stock Price, News & Analysis

BioArctic (NASDAQ Stockholm: BIOA B) announced that its founder, Professor Lars Lannfelt, will receive the prestigious 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering work in Alzheimer's disease research and the development of lecanemab.

Professor Lannfelt, who founded BioArctic in 2003 with Pär Gellerfors, made groundbreaking discoveries about the role of amyloid-beta protein in Alzheimer's disease. These findings led to the development of lecanemab, an antibody treatment that targets specific forms of amyloid-beta in the brain, developed in collaboration with Eisai. The treatment showed positive results in the global Phase 3 Clarity AD trial.

The award ceremony will take place in Bonn in November 2025. The prize, awarded biennially since 2011, recognizes outstanding research in neurodegenerative disorders.

Cree LED, a Penguin Solutions brand, has been awarded the ETQ Innovation Excellence Award 2025 for its innovative implementation of ETQ Reliance quality management system (QMS). The company developed two key solutions: a customer survey module providing instant access to satisfaction data, and a custom quoting solution that automates traditional manual processes.

The custom-built survey module integrates with ETQ Reliance to streamline document management and improve operational efficiency. Additionally, the automated quoting module eliminates manual calculations, reduces errors, and enables dynamic pricing based on customer history, market trends, production quantities, and inventory levels.

Barrick Mining Corporation is facing significant challenges in Mali as the Bamako Commercial Tribunal has placed its Loulo-Gounkoto complex under temporary provisional administration. The company has initiated arbitration through the International Centre for Settlement of Investment Disputes (ICSID) following the Malian government's actions to block gold exports and seize gold stocks. Several Barrick employees remain detained without clear justification. While Barrick maintains legal ownership of the mine, operational control has been transferred to an external administrator. Despite making good faith concessions, Barrick emphasizes it cannot accept terms that would compromise operational viability. The company, which has been operating in Mali for nearly 30 years, remains open to dialogue with the government while pursuing legal remedies through ICSID arbitration to protect its rights under binding Mining Conventions.

BioArctic announced positive interim safety results for exidavnemab in its Phase 2a EXIST study, enabling progression to higher dose cohorts. The study evaluates exidavnemab as a potential disease-modifying treatment for Parkinson's disease and Multiple System Atrophy (MSA). The first cohort demonstrated that the lower dose was safe and well-tolerated compared to placebo in Parkinson's patients. Two new cohorts will now evaluate higher doses in both Parkinson's and MSA patients. Exidavnemab, a monoclonal antibody, selectively targets pathological alpha-synuclein aggregates while preserving physiological forms. The drug has received orphan drug designation in the US and a positive opinion for orphan medicinal product designation in the EU for MSA treatment. The EXIST study is randomized, double-blinded, and placebo-controlled, evaluating safety, tolerability, pharmacokinetics, and various biomarkers.

Hexagon AB has announced the acquisition of APEI, a French aerial mapping company, to strengthen its geospatial data capabilities in Europe. APEI operates a private aircraft fleet for aerial data collection in France, neighboring European countries, and Africa, and has been a long-term Hexagon partner. The acquisition will support growing demand for geospatial content, particularly in France's large mapping market. APEI, with approximately 10 employees, will be integrated into Hexagon's Geosystems division and is expected to generate revenues of around 3 MEUR in 2025 with margins aligned with Hexagon's average levels. The transaction is expected to close by the end of Q2 2025, subject to regulatory approvals.

Crawford & Company (NYSE: CRD-A and CRD-B) has appointed Amy Shore as an independent director effective June 6, 2025, expanding their board to ten directors, including three women. Shore brings over 30 years of leadership experience in financial services, most recently serving as chief transformation officer at Nationwide Insurance. In her previous role as chief customer officer, she managed customer strategy for a $60B enterprise serving 14 million customers. Shore holds a bachelor's degree from Bowling Green State University, where she currently serves as board chair, and has completed executive programs at Northwestern's Kellogg School and UC Berkeley. A 2023 finalist for 50/50 Women on Boards' "50 Women to Watch for Boards," Shore's expertise in business transformation, customer experience, and operational excellence is expected to contribute to Crawford's strategic growth.

Barrick Mining Corporation (NYSE:B) has successfully completed the sale of its 50% stake in the Donlin Gold Project, located in Alaska, to Paulson Advisers LLC and NOVAGOLD Resources Inc. The transaction, valued at $1 billion in cash, marks a significant divestiture for Barrick. The Donlin Gold Project, which was previously jointly owned by Barrick and NOVAGOLD, represents one of North America's largest known undeveloped gold deposits.

ETQ, a Hexagon subsidiary, announced that aerospace parts supplier Farsound has adopted its ETQ Reliance quality management system (QMS). Farsound previously relied on manual methods and basic software tools like Excel and Word, and attempted to build its own QMS before choosing ETQ Reliance. The implementation will be phased, starting with document and training management, followed by nonconformance management and corrective/preventive actions (CAPA). The QMS will be deployed across Farsound's locations in the UK, US, Spain, and Canada, aiming to streamline quality processes, eliminate data silos, and enhance efficiency. The system will be accessible to all employees and is expected to provide Farsound with a competitive advantage in meeting aerospace industry's quality standards.

BioArctic AB (NASDAQ: BIOA B) hosted its Capital Markets Day 2025, outlining ambitious plans to become Sweden's next major pharmaceutical company by 2030. The company's strategy focuses on expanding its pipeline across brain diseases, securing global partnerships, and establishing Leqembi® for Alzheimer's treatment in the Nordic region. Key presentations covered financial outlook, with expected profitability from 2025, R&D strategy featuring their BrainTransporter™ technology enabling up to 70x greater brain exposure for antibodies, and updates on Leqembi® and exidavnemab programs. The event highlighted BioArctic's commitment to innovation in neurology, particularly their progress in Alzheimer's treatment and development of therapies for alpha-synuclein diseases including Parkinson's, Multiple System Atrophy, and Lewy body dementia.